Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9UJ90
UPID:
KCNE5_HUMAN
Alternative names:
AMME syndrome candidate gene 2 protein; Potassium channel subunit beta MiRP4; Potassium voltage-gated channel subfamily E member 1-like protein
Alternative UPACC:
Q9UJ90; Q5JWV7
Background:
The Potassium voltage-gated channel subfamily E regulatory beta subunit 5, known alternatively as AMME syndrome candidate gene 2 protein, Potassium channel subunit beta MiRP4, and Potassium voltage-gated channel subfamily E member 1-like protein, plays a pivotal role in the formation of heteromeric ion channel complexes with voltage-gated potassium (Kv) channel pore-forming alpha subunits. It functions as an inhibitory beta-subunit of the repolarizing cardiac potassium ion channel KCNQ1, essential for generating some native K(+) currents.
Therapeutic significance:
Linked to the AMME complex, a syndrome characterized by glomerulonephritis, sensorineural hearing loss, intellectual disability, midface hypoplasia, and elliptocytosis, understanding the role of Potassium voltage-gated channel subfamily E regulatory beta subunit 5 could open doors to potential therapeutic strategies.